127 related articles for article (PubMed ID: 12481433)
1. MDM2 does not influence p53-mediated sensitivity to DNA-damaging drugs.
McKenzie PP; McPake CR; Ashford AA; Vanin EF; Harris LC
Mol Cancer Ther; 2002 Oct; 1(12):1097-104. PubMed ID: 12481433
[TBL] [Abstract][Full Text] [Related]
2. Selective sensitization to DNA-damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression.
Gibson AA; Harwood FG; Tillman DM; Houghton JA
Clin Cancer Res; 1998 Jan; 4(1):145-52. PubMed ID: 9516963
[TBL] [Abstract][Full Text] [Related]
3. Selective chemosensitization of rhabdomyosarcoma cell lines following wild-type p53 adenoviral transduction.
Shetty S; Taylor AC; Harris LC
Anticancer Drugs; 2002 Sep; 13(8):881-9. PubMed ID: 12394275
[TBL] [Abstract][Full Text] [Related]
4. Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification.
Knights CD; Liu Y; Appella E; Kulesz-Martin M
J Biol Chem; 2003 Dec; 278(52):52890-900. PubMed ID: 14555661
[TBL] [Abstract][Full Text] [Related]
5. Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting.
D'Orazi G; Marchetti A; Crescenzi M; Coen S; Sacchi A; Soddu S
J Gene Med; 2000; 2(1):11-21. PubMed ID: 10765501
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
Arriola EL; Lopez AR; Chresta CM
Oncogene; 1999 Jan; 18(4):1081-91. PubMed ID: 10023685
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells.
Shimada H; Liu TL; Ochiai T; Shimizu T; Haupt Y; Hamada H; Abe T; Oka M; Takiguchi M; Hiwasa T
Oncogene; 2002 Feb; 21(8):1208-16. PubMed ID: 11850840
[TBL] [Abstract][Full Text] [Related]
8. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
9. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
Zhou M; Gu L; Findley HW; Jiang R; Woods WG
Cancer Res; 2003 Oct; 63(19):6357-62. PubMed ID: 14559824
[TBL] [Abstract][Full Text] [Related]
10. DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms.
Li C; Chen L; Chen J
Mol Cell Biol; 2002 Nov; 22(21):7562-71. PubMed ID: 12370303
[TBL] [Abstract][Full Text] [Related]
11. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.
Mayo LD; Dixon JE; Durden DL; Tonks NK; Donner DB
J Biol Chem; 2002 Feb; 277(7):5484-9. PubMed ID: 11729185
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.
Zhou BP; Liao Y; Xia W; Zou Y; Spohn B; Hung MC
Nat Cell Biol; 2001 Nov; 3(11):973-82. PubMed ID: 11715018
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting effect of murine double minute-2 oncogene on apoptosis induced by retroviral-mediated wild-type p53.
Guo H; Liu T; Gao J
Chin Med J (Engl); 1998 Dec; 111(12):1102-6. PubMed ID: 11263374
[TBL] [Abstract][Full Text] [Related]
14. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells.
Yang HL; Dong YB; Elliott MJ; Wong SL; McMasters KM
Cancer Gene Ther; 2001 Apr; 8(4):241-51. PubMed ID: 11393276
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
16. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
Chen L; Agrawal S; Zhou W; Zhang R; Chen J
Proc Natl Acad Sci U S A; 1998 Jan; 95(1):195-200. PubMed ID: 9419352
[TBL] [Abstract][Full Text] [Related]
18. MDM2 oncogene as a target for cancer therapy: An antisense approach.
Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
[TBL] [Abstract][Full Text] [Related]
19. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5.
Dai MS; Lu H
J Biol Chem; 2004 Oct; 279(43):44475-82. PubMed ID: 15308643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
